Dr. Teera reveals that the US FDA has approved the use of the Bivalen vaccine as the main component for the American people instead of the original vaccine, the first dose – the booster dose. It can reduce the risk of serious illness 16 times and reduce the risk of death 13 times compared to the unvaccinated group.
On January 27, Dr. Thira Worathanarat, Chulalongkorn University Faculty of Medicine Posted a message via Facebook, stating that yesterday, worldwide, there were 147,330 more people, 744 more deaths, a total of 674,168,661 people, and a total of 6,753,161 deaths.
The top 5 most infected are Japan, South Korea, Taiwan, the United States and Russia.
As of yesterday, in the number of new infections, countries from Europe and Asia occupied seven of the top 10 and 16 of the top 20 globally.
The number of new infections per day worldwide currently from Asia and Europe together represent 90.72 percent of the entire world, while the number of deaths accounts for 82.39 percent
…US FDA meeting update
A key meeting was held last night regarding the VRBPAC committee’s public vaccination plan.
Meeting almost six o’clock in America. or six o’clock in the morning from Thailand today
In essence, the judges voted 21:0 in favor of the bivalent vaccine (containing the original strain plus the BA.4/5 strain) as the main component of vaccines offered to the American public. It will replace the traditional vaccine from the first dose to the booster.
The information presented suggests that those who received the bivalent vaccine had a 16 times greater reduction in the risk of serious illness and a 13 times greater reduction in the risk of death compared to the unvaccinated group.
And those who received the bivalent vaccine had a threefold reduction in the risk of serious illness and a twofold reduction in the risk of death compared to those who received the vaccine without the booster dose of the bivalent vaccine.
Another key point that will come up at the meeting is Discuss vaccination guidelines in the future how to do There is a draft proposal to be considered according to the news the other day that it will offer injections once a year to people who have received the vaccine before (Figure 1), but it was concluded that VRBPAC has not yet been decided and it is expected that VRBPAC will let the US CDC Advisory Committee on Immunization Practices reconsider.
the move above This reflects the view that the bivalent vaccine will be the main preventive method used to prevent COVID-19. And in the future, vaccines will be updated according to the predicted fires to be suitable for the epidemic strain. As for the long-term booster vaccination, it is not clear. Need to continue following each other
… Long COVID update
Landry M and colleagues from George Washington University, USA. Published the results of research in the March 2023 issue of the Journal of Infectious Diseases Emerging Infectious Diseases studied between July 2021 and March 2022 among 1,338 students, faculty members and university personnel who were infected with COVID-19. More than a third (36%) of people experience Prolonged COVID.
Prolonged COVID problems are most common among infected people with symptoms. and/or have multiple symptoms, people with underlying diseases, women, people who have not had all the vaccines, people who smoke or have smoked before It has also been found that a complete booster vaccination will reduce the risk of Long COVID about half. Compared to the group that did not receive the booster vaccine. or groups that have not been vaccinated
…For Thailand, us
protection against infection or re-infection is best
Wearing a mask correctly and consistently during everyday life outside the home will greatly reduce the risk.
refer
1. Vaccines and Related Biological Products Advisory Committee January 26, 2023 Meeting. United States FDA
2. Live blog: Tracking the FDA advisory panel meeting on Covid vaccines. STAT News. 27 January 2023
3. FDA Advisory Committee Votes to Merge Composition of Primary and Fortified COVID-19 Vaccine Strains. Contagion Live. 27 January 2023
4. Landry M et al. Postacute Sequelae of SARS-CoV-2 in a University Setting. Emerging Infectious Diseases. Volume 29, Number 3 — March 2023
